Bevacizumab for treatment of choroidal neovascularization secondary to candida chorioretinitis

Georgios Makragiannis, Kaveh Vahdani, Ester Carreño*, Richard W.J. Lee, Andrew D. Dick, Adam H. Ross

*Corresponding author for this work

Research output: Contribution to journalArticle (Academic Journal)peer-review

2 Citations (Scopus)
360 Downloads (Pure)


Purpose: To report a case of juxtafoveal choroidal neovascularization in a patient with candida chorioretinitis successfully treated with intravitreal bevacizumab. Methods: Case report. Results: A 45-year-old woman previously treated for candida chorioretinitis was presented with reduced vision in the left eye. The patient was investigated with ophthalmoscopy, fluorescein angiography, and optical coherence tomography (OCT). Following initial treatment, fundus examination, fluorescein angiography, and OCT of the right eye revealed a secondary juxtafoveal classic choroidal neovascularization. Following a single intravitreal injection of bevacizumab, the patient had excellent visual recovery, with absence of subretinal or intraretinal fluid in the OCT. Conclusions: Bevacizumab was effective in treatment of choroidal neovascularization associated with candida chorioretinitis.

Original languageEnglish
Pages (from-to)781-785
Number of pages5
JournalInternational Ophthalmology
Issue number2
Early online date30 Mar 2017
Publication statusPublished - 1 Apr 2018


  • Bevacizumab
  • Candida
  • Chorioretinitis
  • Choroidal neovascular membrane


Dive into the research topics of 'Bevacizumab for treatment of choroidal neovascularization secondary to candida chorioretinitis'. Together they form a unique fingerprint.

Cite this